Intercell revenues up
Biotech firm reports revenues of EUR61.68m for the full year ended December 31, 2009,
The company, however, posted a net loss of EUR18.37m for the full year 2009, or EUR0.39 per diluted share, compared to net income of EUR17.17m, or EUR0.37 per diluted share, for the prior year period. Operating loss was EUR30.46m, compared to EUR13.81m for the year ago period.
Gerd Zettlmeissl, CEO of Intercell, said: "A major challenge facing our industry is identifying ways to improve healthcare in both developed and developing nations. The patch technology program is among our initiatives aspiring to bring innovation to all countries. We also face the challenge of overcoming concerns about injected vaccines. Other companies have attempted to address these concerns through development of oral and nasal vaccines - with limited success. We believe our patch technology can meet these challenges and be an important stimulus for future improvements."